Stryker Corporation (SYK) Position Held by Douglass Winthrop Advisors LLC
Douglass Winthrop Advisors LLC held its position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 10,290 shares of the medical technology company’s stock at the close of the second quarter. Douglass Winthrop Advisors LLC’s holdings in Stryker Corporation were worth $1,428,000 as of its most recent filing with the SEC.
A number of other large investors have also bought and sold shares of SYK. Lockheed Martin Investment Management Co. acquired a new stake in shares of Stryker Corporation during the 2nd quarter worth about $1,249,000. JPMorgan Chase & Co. boosted its stake in shares of Stryker Corporation by 276.9% during the 1st quarter. JPMorgan Chase & Co. now owns 269,555 shares of the medical technology company’s stock worth $35,487,000 after purchasing an additional 198,035 shares during the last quarter. BB&T Corp boosted its stake in shares of Stryker Corporation by 5.7% during the 2nd quarter. BB&T Corp now owns 56,546 shares of the medical technology company’s stock worth $7,847,000 after purchasing an additional 3,060 shares during the last quarter. British Columbia Investment Management Corp boosted its stake in shares of Stryker Corporation by 10.7% during the 1st quarter. British Columbia Investment Management Corp now owns 133,596 shares of the medical technology company’s stock worth $17,588,000 after purchasing an additional 12,871 shares during the last quarter. Finally, Hartland & Co. LLC boosted its stake in shares of Stryker Corporation by 1.4% during the 1st quarter. Hartland & Co. LLC now owns 1,860 shares of the medical technology company’s stock worth $245,000 after purchasing an additional 25 shares during the last quarter. Hedge funds and other institutional investors own 74.18% of the company’s stock.
SYK has been the topic of several analyst reports. BidaskClub cut shares of Stryker Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Zacks Investment Research raised shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 price target on the stock in a research note on Monday, July 17th. Stifel Nicolaus raised their price target on shares of Stryker Corporation from $151.00 to $158.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Cowen and Company reaffirmed a “buy” rating and set a $160.00 price target (up from $150.00) on shares of Stryker Corporation in a research note on Sunday, July 30th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $155.00 target price (down from $158.00) on shares of Stryker Corporation in a research report on Thursday, August 24th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $145.73.
ILLEGAL ACTIVITY WARNING: “Stryker Corporation (SYK) Position Held by Douglass Winthrop Advisors LLC” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/09/16/stryker-corporation-syk-position-held-by-douglass-winthrop-advisors-llc.html.
Stryker Corporation (NYSE:SYK) opened at 143.88 on Friday. The company has a 50-day moving average of $143.77 and a 200 day moving average of $138.65. The stock has a market cap of $53.82 billion, a price-to-earnings ratio of 32.12 and a beta of 0.81. Stryker Corporation has a 12-month low of $106.48 and a 12-month high of $148.84.
Stryker Corporation (NYSE:SYK) last announced its earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.51 by $0.02. The firm had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.98 billion. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The company’s revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.39 earnings per share. Equities analysts anticipate that Stryker Corporation will post $6.46 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be given a dividend of $0.425 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a yield of 1.18%. Stryker Corporation’s payout ratio is currently 37.95%.
In other Stryker Corporation news, insider Graham A. Mclean sold 1,124 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total transaction of $164,396.24. Following the completion of the sale, the insider now owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Floyd sold 19,305 shares of the company’s stock in a transaction that occurred on Wednesday, July 12th. The stock was sold at an average price of $144.56, for a total value of $2,790,730.80. The disclosure for this sale can be found here. Insiders have sold 25,429 shares of company stock valued at $3,686,927 in the last ninety days. Company insiders own 7.40% of the company’s stock.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.